Avid Bioservices Inc (CDMO)

[cjgaddy]

CEO S.King’s 3-9-15 ROTH/DanaPT Talk (40 Slides/24mins)

Mar8-11 2015: “Roth’s 27th Annual OC Growth Stock Conf.”, DanaPT, CA
http://www.roth.com/main/Page.aspx?PageID=7207

CEO Steven King’s 24 min. Presentation – Roth/DanaPT CA
3-9-2015 10amPT WEBCAST Replay: http://ir.peregrineinc.com/events.cfm
Direct Replay: http://wsw.com/webcast/roth29/pphm







































































Slide37/S.King(17:57): “We have a wholly-owned subsidiary, Avid Bioservices, which is a profitable business. In fact, if you look at the revenues generated from Avid, they more or less cover our overall G&A, so as we go out and raise capital, more of that goes directly to fund R&D efforts, which of course lead to the big increases in evaluation in the future. We’ve had nice growth over the last several years, and, again, we are in the process of expanding this facility. This is be a state-of-the-art facility, driven by both client interest as well as the work going on at Peregrine with Bavi and other compounds in development. This more than doubles our overall mfg. capacity, so creating a lot of addl. revenue-generating potential as well as preparing us for Bavi commercialization in the future. And this can be very important, because if you look at the recent news from the immune-oncology space, probably the biggest news came out of Bristol-Meyers was their PD-1 compound, and with the compound they had interim data looks; they stopped the trial based on positive results from that interim data look, and as little as 3 mos. later they’ve already now received FDA approval. So, it shows how quickly in this space that compounds can move. Part of this is having clinical data, and part of it is being in a position to mfg. the drug, so it’s a big benefit having this type asset that generates revenues and also prepares us for that success.”








.
Roth Capital /Joe Pantginis - init. 7-15-10 Buy/PT=$10, CURR: Buy/$5 http://www.roth.com
. . .Universe (click link bottom right): http://roth.bluematrix.com/docs/pdf/BLUE.pdf
. . .12-11-14: Roth maintains PPHM PT=$5 ("we believe visibility from the broadening bavi profile & partnering potential should drive the stock in ‘15") http://tinyurl.com/k95gxum
. . .9-10-14: Roth maintains PPHM PT=$5 ("broadening bavituximab profile & partnering potential should drive the stock") http://tinyurl.com/qgkqm75
. . .7-15-14: Roth maintains PPHM PT=$5 ("remains encouraged by progress in FY14") http://tinyurl.com/nwacgev
. . .6-28-13: Roth lowers PPHM PT 7=>$5 (following PPHM's 6-27-13 press release)
. . .6-3-13: Roth raises PPHM PT 4=>$7 ("ASCOdata+FDA_ph3 agreement & visibility should represent the final potential triggers to conclude a partnership deal.") http://tinyurl.com/kkvddt2
. . .1-14-13: Roth raises PPHM PT 2.70=>$4.00 ("partnering discussions have new found life") http://tinyurl.com/a9t29lb
. . .1-7-13: Roth ups Neutral to BUY, PT 1.25=>$2.70 (after 2nd-Line NSCLC Review Upd) http://tinyurl.com/bfj7mva
. . .12-11-12: Roth ups PT $.70=>$1.25 after Cotara Ph3 design approval & 12-10-12/10Q-CC.
. . .9-24-12: Roth cuts PT $9=>$.70 after PPHM PR about 2nd-Line NSCLC trial data problems.
. . .9-10-12: Roth ups PT $5=>$9 ("highly encouraged by 2ndLine NSCLC clinical data") http://tinyurl.com/9blrqk7
. . .8-15-12: Roth adds PPHM to focus list as a Top Biotech Pick: http://tinyurl.com/9rx5bps
. . .5-21-12: Roth ups PT $3.30=>$5 ("impressed by the strong 2ndLine NSCLC clinical data") http://tinyurl.com/cnghzyv